Aspargo Labs, which makes an oral liquid suspension formulation of a drug for erectile dysfunction, withdrew its plans for direct listing on the NYSE on Wednesday. The company originally filed in January 2025; it had not updated its prospectus since then. The Registered Stockholders had planned to sell up to 177 million shares.
The New York, NY-based company was founded in 2019 and had planned to list on the NYSE under the symbol AAGO. on the deal.
